France Diabetic Retinopathy Market Size & Outlook, 2025-2033
France Diabetic Retinopathy Market Insights
- As highlighted in Reed Intelligence analysis, the France Diabetic Retinopathy Market, worth USD 286.5 Million in 2024, is forecasted to achieve USD 542.14 Million by 2033.
- The France market is anticipated to grow at a CAGR of 7.3% during the period 2026–2033.
- By 2024, Proliferative Diabetic Retinopathy represented the largest share of the By Type market size.
- Proliferative Diabetic Retinopathy is expected to remain the key growth driver within By Type, registering the fastest CAGR during the forecast period.
![France Diabetic Retinopathy Market Size, Share & Growth Report By [2033]](https://reedintelligence.com/uploads/charts/france-diabetic-retinopathy-market-france-by-type-35528.png)
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- France accounted for 3.14% of the global Diabetic Retinopathy Market size in 2024.
- By 2033, United States is expected to remain the top global market in terms of size.
- Within Europe, Germany is forecasted to dominate the regional Diabetic Retinopathy Market size by 2033.
- Germany will be the fastest-growing market in Europe, projected to achieve USD 914.25 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 286.5 Million |
| Market Size In 2033 | USD 542.14 Million |
| Largest segment | Proliferative Diabetic Retinopathy |
| Units | Revenue in USD Million |
| CAGR | 7.3% (2025-2033) |
| Segmnetation Covered | |
| By Type |
|
| By Treatment Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
France Diabetic Retinopathy Market By Type 2025-2033 (USD Million)
| By Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | 184.22 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Non-proliferative Diabetic Retinopathy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
France Diabetic Retinopathy Market By Treatment Type 2025-2033 (USD Million)
| By Treatment Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Anti-VEGF Drug | XX.x | XX.x | XX.x | 114.63 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Steroid Implants | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Laser Surgeries | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Vitrectomy | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
